Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]
Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 study of Rocbrutinib in relapsed or refractory mantle cell lymphoma is active and not recruiting. Sponsor: Guangzhou Lupeng Pharma…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recr…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. [Phase 2]
Phase 2 trial evaluating consolidation with loncastuximab tesirine after a short course of immunochemotherapy in BTKi-treated or intolerant …
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial at City of Hope is evaluating a three-drug combination of acalabrutinib, obinutuzumab, and glofitamab for relapsed …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
This entry covers the MANTLE-FIRST BIO clinical study, which aims to glean biological insights from first relapsed/refractory mantle cell ly…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: The Role of 18F-FDG-PET for Staging and Prognostication
A completed clinical trial update evaluating the role of 18F-FDG-PET imaging for staging and prognostication in mantle cell lymphoma.
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. [Phase 1]
This is a Phase 1 dose-escalation and expansion study evaluating intratumoral ONM-501 alone and in combination with cemiplimab in patients w…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating ultra low dose radiation delivered before or after a chemotherapy-free targeted therapy in patients w…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 study update for brexucabtagene autoleucel (KTE-X19) in adult Japanese patients with relapsed/refractory mantle cell lymphoma or rel…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of pirtobrutinib in combination with rituximab for Mantle Cell Lymphoma; currently…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma [Phase 1]
An ongoing Phase 1 clinical trial update for AS-1763 in adults with previously treated B-cell malignancies, including chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease [Phase 2]
A Phase 2 clinical trial is evaluating the combination of orelabrutinib, lisaftoclax, and rituximab in untreated, high-risk Mantle Cell Lymp…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study
A single-center cohort study is assessing biomarkers of cardiovascular complications in patients treated with second-generation BTK inhibito…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial [Phase 4]
Phase 4 multi-center prospective trial evaluating ZSDT for relapsed/refractory mantle cell lymphoma after BTK inhibitor failure; the study i…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 clinical trial update on Pemigatinib in relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell lymphoma and marg…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating obinutuzumab, zanubrutinib, and lenalidomide as first-line treatment for mantle cell lymphoma, with t…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma [NA]
This clinical trial update reports an ongoing study evaluating a three-drug regimen (pomalidomide plus orelabrutinib and zuberitamab) in unt…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of pevonedistat in combination with ibrutinib for relapsed or refractory chronic lympho…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of modified CD19 CAR T cells with acalabrutinib for relapsed or refractory mantle cel…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) [Phase 2]
Phase 2 study evaluating ICP-248 for efficacy and safety in relapsed or refractory mantle cell lymphoma, currently recruiting (APEX-06).
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating ibrutinib in combination with rituximab and consolidation chemotherapy for young patients with newl…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Disease Registry of Patients With Mantle Cell Lymphoma
This is a disease registry study collecting data on patients with Mantle Cell Lymphoma, sponsored by AstraZeneca. The study status is COMPLE…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of acalabrutinib and rituximab for previously untreated mantle cell lymphoma and is c…